Led · Equity · Jan 2024

Beckley Psytech is a British privately-held psychedelic drug developer focused on short-duration psychedelic therapies. Its two primary clinical programs are intranasal 5‑MeO‑DMT (BPL‑003), in a Phase IIb study targeting 225 moderate-to-severe TRD patients with a readout expected in H2 2024, and intravenous psilocin (ELE‑101), in a Phase I/IIa study with topline results expected in H1 2024. The company positions these shorter-duration candidates as potentially more scalable and efficient than longer-acting psychedelic-assisted therapies, which could improve patient access. Beckley and its partners are exploring digital patient-support tools and planning for future commercialization as part of development efforts. Financially, Beckley received a $50M strategic investment from atai—$40M primary and $10M secondary—which granted atai a 35.47% stake and board representation. The company previously raised an $80M Series B (upsized from $50M) in summer 2021. Beckley Psytech is a clinical-stage, privately held company developing a broad pipeline of psychedelic compounds to address neurological and psychiatric disorders. Its near-term clinical programs include a Phase 1b low-dose psilocybin trial in patients with SUNHA and a planned Phase 1 dose-ranging study of an intranasal 5-MeO-DMT formulation ahead of a Phase 2 trial in treatment-resistant depression. The company plans to expand its pipeline with new, unique and proprietary psychedelic compounds. Beckley Psytech leverages expertise developed over more than 20 years by the Beckley Foundation and was founded in 2019. It is based in Oxford, United Kingdom and states a vision for integrating clinically validated psychedelic medicines into modern medical practice. The company recently completed an oversubscribed Series B financing of $80 million to accelerate its clinical development programs. Beckley Psytech is a UK psychedelic medicine company and spin-out of the Beckley Foundation focused on turning psychedelic compounds into licensed pharmaceuticals. Its immediate focus is the development of 5-MeO-DMT as a treatment for neuropsychiatric diseases and the company is preparing to begin a Phase 1 clinical trial. The team also plans to explore other psychedelic agents targeting orphan diseases. The company was founded last year by Lady Amanda Feilding and CEO Cosmo Feilding Mellen and maintains a Scientific Advisory Board including Dr. Robin Carhart-Harris, Prof. Matthew Johnson and Prof. Guy Goodwin. Financially, the company has recently completed follow-on fundraising to push its drug development pipeline toward clinical trials.

Participated · Series B · Apr 2020

COMPASS Pathways develops COMP360, a proprietary synthetic psilocybin formulation delivered with psychological support to treat individuals who do not respond to current therapies. The company has earned FDA Breakthrough Therapy status and the UK ILAP designation for COMP360 in treatment‑resistant depression (TRD). It completed a phase 2b study showing significant symptom improvement with a 25mg dose and has launched the largest‑ever randomized, controlled, double‑blind phase 3 programme for TRD. COMPASS is also running phase 2 trials in PTSD and anorexia nervosa and investing in digital technology to support its therapy. The company announced a large private financing to support its clinical programmes, commercial planning and research through roughly late 2025. Compass Pathways is a London-based mental health care company focused on developing psilocybin therapy for treatment-resistant depression. Its lead program is a large-scale psilocybin therapy clinical trial being conducted at 20 sites across nine countries in Europe and North America. The company received FDA Breakthrough Therapy designation for its psilocybin therapy program in 2018. Compass intends to use the Series B proceeds to expand its lead program, support research into additional indications for psilocybin therapy, advance its preclinical pipeline, develop digital technologies, and establish new academic and clinical research partnerships. Leadership includes CEO and co-founder George Goldsmith and President, Chief Business Officer and co-founder Lars Wilde.